WO2005067895A1 - Compositions pharmaceutiques a liberation controlee - Google Patents
Compositions pharmaceutiques a liberation controlee Download PDFInfo
- Publication number
- WO2005067895A1 WO2005067895A1 PCT/EP2005/000322 EP2005000322W WO2005067895A1 WO 2005067895 A1 WO2005067895 A1 WO 2005067895A1 EP 2005000322 W EP2005000322 W EP 2005000322W WO 2005067895 A1 WO2005067895 A1 WO 2005067895A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- controlled release
- water soluble
- soluble hydrophilic
- formulation according
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- This invention relates to pharmaceutical compositions of the I-acetoxyethyl ester of the antibiotic compound cefuroxime, known as cefuroxime axetil. More particularly this invention relates to controlled release formulations of cefuroxime axetil and a process for the preparation thereof.
- Drugs containing an active ingredient with a relatively short biological half life often need to be administered several times a day in order to achieve the desired therapeutic effect.
- controlled delivery systems have been developed which avoid the need for such multiple administrations. Controlled release systems not only reduce the frequency of administration but also contribute to improved patient compliance and can reduce side effects.
- one object of the present invention is the provision of a controlled release formulation of cefuroxime axetil.
- the present invention provides a controlled release pharmaceutical formulation comprising cefuroxime axetil and a water soluble hydrophilic agent.
- a suitable water soluble hydrophilic agent according to the present invention is sodium chloride.
- the present invention provides a process for the preparation of a controlled release pharmaceutical formulation of cefuroxime axetil comprising mixing cefuroxime axetil with a water soluble hydrophilic agent.
- the cefuroxime axetil may be in any form, e.g. in a crystalline form, an amorphous form, or in the form of a solid solution in a polymer.
- the cefuroxime axetil is in the form of a solid solution in a polymer.
- Suitable polymers include homo- and copolymers of a polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide and cellulose.
- Suitable water soluble hydrophilic agents are those having a solubility in water at room temperature of at least 1mg/1000ml.
- Suitable water soluble hydrophilic agents include sodium chloride, potassium chloride, sulphates of sodium, potassium or magnesium, citric acid and salts thereof, lactic acid and salts thereof, fumaric acid and salts thereof, sodium carbonate, sodium bicarbonate, sodium lauryl sulphate, lactose, sucrose, tween, polyethylene glycol, mannitol, sorbitol and cetrimide.
- Preferred water soluble hydrophilic agents include sodium chloride, potassium chloride, sulphates of sodium, potassium or magnesium, citric acid and salts thereof, lactic acid and salts thereof, fumaric acid and salts thereof, sodium carbonate and sodium bicarbonate,. More preferred water soluble hydrophilic agents include sodium chloride, potassium chloride, sulphates of sodium, potassium or magnesium. In particular preferred water soluble hydrophilic agents are sodium chloride or potassium chloride.
- the cefuroxime axetil active ingredient and the water soluble hydrophilic agent are preferably present in a ratio between the range of 1 :0.1 to 0.1:1.
- the amount of water soluble hydrophilic agent in the formulations of the present invention is preferably at least 5% by weight, e.g. at least 10% by weight.
- a formulation according to the present invention may optionally comprise a rate controlling polymer or a mixture of rate controlling polymers.
- Suitable rate controlling polymers include water soluble polymers, for instancecellulose derivatives, acrylic acid derivatives, polyoxyethylene glycols and polyvinyl alcohols. Polysaccharides or N-vinyl-2- pyrrolidone/vinyl acetate copolymers are excluded.
- Preferred rate controlling polymers are cellulose derivatives and acrylic acid derivatives. Suitable cellulose derivatives include carboxymethyl cellulose, calcium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose and ethyl cellulose.
- a preferred rate controlling polymer is a commercially available hydroxypropylmethyl cellulose e.g. Methocel K 4 MCR, Methocel K 4 M Premium. If desired, variation of the dissolution profile can be achieved by adjusting the ratio between the water soluble hydrophilic agent(s) and a rate controlling polymer(s).
- a formulation according to the present invention may comprise additional ingredients such as one or more further active drug compound(s) and/or one or more pharmaceutically acceptable excipients as conventionally used, such as for instance diluents, e.g. lactose, , mannitol, starch; binders, e.g. polyvinyl pyrrolidone (PVP),; lubricants/glidants.e.g. magnesium stearate, talc, stearic acid, colloidal sodium dioxide; and also flavoring agents, taste masking agents, colouring agents, pigments, and preservatives.
- diluents e.g. lactose, , mannitol, starch
- binders e.g. polyvinyl pyrrolidone (PVP),
- lubricants/glidants e.g. magnesium stearate, talc, stearic acid, colloidal sodium dioxide
- flavoring agents taste masking agents, colouring
- the controlled release formulations of the present invention are particularly suitable for oral administration.
- Any orally administrable dosage form is contemplated by the present invention, in particular a tablet, a capsule, a pellet, or a sachet form.
- the dosage form may be prepared according to conventional methods. For instance methods for the preparation of tablets or capsules may include direct compression, dry granulation, wet granulation. For dry granulation processes one suitable method of granule formation is compaction.
- the controlled release formulation is in the form a tablet or capsule.
- a tablet according to the present invention may be uncoated or coated, e.g. by a film or other conventional coating, using known methods.
- the formulation is a once daily administrable formulation, e.g. a tablet for once daily administration.
- a unit dosage form of a formulation according to the present invention may comprise an amount of cefuroxime axetil as conventional.
- the pharmaceutical formulations according to the present invention provide controlled release of cefuroxime axetil.
- the present invention is further illustrated by the following non-limiting examples.
- cefuroxime axetil, Mg. Stearate, Avicel and sodium chloride are mixed and compressed into tablet form using a 16 mm round punch.
- the resulting tablets are then passed through a sieve number 16 to get granules.
- the granules are then lubricated with the remaining ingredients.
- the lubricated material is compressed into tablets using a 19X9 mm caplet shape punch.
- cefuroxime axetil, Sodium chloride and Avicel are mixed and compacted using roller compactor.
- Compacted ribbons passed through a sieve number 16 to get granules.
- the granules are then mixed with the remaining ingredients.
- the mixed material is compressed into tablets using a 19 X 9 mm caplet shape punch.
- Dissolution medium USP II; 0.1 N HCL; 100 rpm Time (Hrs) % of drug release 1 6 2 13 4 26 6 36 8 43 10 49 12 52 16 57
- cefuroxime axetil, Sodium chloride and Avicel are mixed and compacted using roller compactor.
- Compacted ribbons passed through a sieve number 16 to get granules.
- the granules are then mixed with the remaining ingredients.
- the mixed material is compressed into tablets using a 19X9 mm caplet shape punch.
- Dissolution medium USP II; 0.1 N HCL; 100 rpm Time (Hrs) % of drug release 1 13 2 46 4 73 6 81 8 83 10 84
- cefuroxime axetil, Mg. Stearate, and Avicel are mixed and compressed into tablet form using a 16 mm round punch.
- the resulting tablets are then passed through a sieve number 16 to get granules.
- the granules are then lubricated with the remaining ingredients.
- the lubricated material is compressed into tablets using a 19X9 mm caplet shape punch.
- Dissolution medium USP II; Phosphate buffer pH 6.8; 50 rpm
- cefuroxime axetil, Mg. Stearate, Avicel and Methocel are mixed and compressed into tablet form using a 16 mm round punch.
- the resulting tablets are then passed through a sieve number 16 to get granules.
- the granules are then lubricated with the remaining ingredients.
- the lubricated material is compressed into tablets using a 19X9 mm caplet shape punch.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0400971A GB0400971D0 (en) | 2004-01-16 | 2004-01-16 | Pharmaceutical compositions |
GB0400971.8 | 2004-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005067895A1 true WO2005067895A1 (fr) | 2005-07-28 |
Family
ID=31726296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/000322 WO2005067895A1 (fr) | 2004-01-16 | 2005-01-14 | Compositions pharmaceutiques a liberation controlee |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0400971D0 (fr) |
WO (1) | WO2005067895A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009026725A1 (fr) * | 2007-08-31 | 2009-03-05 | Noveko Inc. | Compositions antimicrobiennes et fibres incorporant de telles compositions |
US8905034B2 (en) | 2010-11-05 | 2014-12-09 | Salutaris Llp | Ergonomic protective air filtration devices and methods for manufacturing the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062559A1 (fr) * | 1998-05-29 | 1999-12-09 | Bernard Charles Sherman | Comprimes pharmaceutiques comprenant du cefuroxime axetil |
WO2000056286A1 (fr) * | 1999-03-19 | 2000-09-28 | Ranbaxy Laboratories Limited | Procede de preparation d'une forme posologique orale biodisponible de cefuroxime axetil |
WO2002036126A1 (fr) * | 2000-10-30 | 2002-05-10 | Lupin Limited | Composition de cefuroxime axetil a liberation lente et a desintegration rapide |
US20020136764A1 (en) * | 2000-02-24 | 2002-09-26 | Rudnic Edward M. | Antibiotic product, use and formulation thereof |
US6534494B1 (en) * | 1997-09-29 | 2003-03-18 | Ranbaxy Laboratories Limited | Process for the preparation of cefuroxime axetil in an amorphous form |
WO2004019901A2 (fr) * | 2002-08-30 | 2004-03-11 | Orchid Chemicals & Pharmaceuticals Ltd. | Composition pharmaceutique a liberation prolongee |
-
2004
- 2004-01-16 GB GB0400971A patent/GB0400971D0/en not_active Ceased
-
2005
- 2005-01-14 WO PCT/EP2005/000322 patent/WO2005067895A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534494B1 (en) * | 1997-09-29 | 2003-03-18 | Ranbaxy Laboratories Limited | Process for the preparation of cefuroxime axetil in an amorphous form |
WO1999062559A1 (fr) * | 1998-05-29 | 1999-12-09 | Bernard Charles Sherman | Comprimes pharmaceutiques comprenant du cefuroxime axetil |
WO2000056286A1 (fr) * | 1999-03-19 | 2000-09-28 | Ranbaxy Laboratories Limited | Procede de preparation d'une forme posologique orale biodisponible de cefuroxime axetil |
US20020136764A1 (en) * | 2000-02-24 | 2002-09-26 | Rudnic Edward M. | Antibiotic product, use and formulation thereof |
WO2002036126A1 (fr) * | 2000-10-30 | 2002-05-10 | Lupin Limited | Composition de cefuroxime axetil a liberation lente et a desintegration rapide |
WO2004019901A2 (fr) * | 2002-08-30 | 2004-03-11 | Orchid Chemicals & Pharmaceuticals Ltd. | Composition pharmaceutique a liberation prolongee |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009026725A1 (fr) * | 2007-08-31 | 2009-03-05 | Noveko Inc. | Compositions antimicrobiennes et fibres incorporant de telles compositions |
US8905034B2 (en) | 2010-11-05 | 2014-12-09 | Salutaris Llp | Ergonomic protective air filtration devices and methods for manufacturing the same |
Also Published As
Publication number | Publication date |
---|---|
GB0400971D0 (en) | 2004-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0914119B1 (fr) | Procede de preparation de formes solides de valsartan administrees par voie orale | |
CN106943355B (zh) | 药物组合物 | |
US6932981B2 (en) | Rapidly disintegrating sustained release cefuroxime axetil composition | |
ZA200502925B (en) | Dosage form of sodium ibuprofen. | |
CA2182004C (fr) | Comprimes enrobes de paracetamol et de domperidone | |
EP2162119A2 (fr) | Formulation pharmaceutique stable pour un inhibiteur de dpp-iv | |
WO2004110422A1 (fr) | Comprimes a liberation controlee de metformine | |
ZA200501541B (en) | Bicifadine formulation | |
WO2004019901A2 (fr) | Composition pharmaceutique a liberation prolongee | |
MXPA06015095A (es) | Formulacion oral de liberacion sostenida de tedisamil con propiedades de retencion gastrica. | |
JP2005533774A (ja) | ジバルプロエクスソジウムの放出遅延剤 | |
US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
WO2005067895A1 (fr) | Compositions pharmaceutiques a liberation controlee | |
AU2005235237A1 (en) | Clarithromycin extended release formulation | |
EP1720524A2 (fr) | Comprimes a liberation prolongee de clarithromycine | |
US20080220064A1 (en) | Extended release matrix formulations of morphine | |
US20040096496A1 (en) | Sustained release pharmaceutical composition of a cephalosporin antibiotic | |
WO2005020978A1 (fr) | Comprimes de gabapentine a liberation prolongee et a administration par voie orale et leurs procedes de preparation | |
US20160058730A1 (en) | Pharmaceutical compositions of teriflunomide | |
US9492459B2 (en) | Pharmaceutical composition of linezolid | |
KR20110105550A (ko) | 에카베트 또는 그의 염을 함유하는 경구용 정제 | |
WO2009016577A2 (fr) | Composition pharmaceutique comprenant de l'atorvastatine et de la niacine | |
KR20060058415A (ko) | 아목시실린 및 클라불란산 또는 그의 염의 혼합물 함유조성물 및 그의 제조방법 | |
WO2013109203A1 (fr) | Formulations en comprimés comprenant du cefditoren pivoxil | |
WO2014051532A1 (fr) | Formulations en comprimé pharmaceutique comprenant du cefdinir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |